MEDIPOST Files IND Amendment for Phase III Knee Osteoarthritis Trial

Biotechnology company aims to advance stem cell therapy for degenerative joint condition.

Published on Feb. 13, 2026

Got story updates? Submit your updates here. ›

MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies, announced it has filed an Investigational New Drug (IND) amendment with the U.S. Food and Drug Administration (FDA) to initiate a Phase III clinical trial evaluating its investigational cell therapy for knee osteoarthritis. Patient enrollment is expected to begin in the first half of 2026.

Why it matters

Knee osteoarthritis is a leading cause of pain and loss of mobility, highlighting the need for therapies that go beyond symptom management. MEDIPOST's planned Phase III study is intended to further evaluate the potential role of regenerative cell therapy in addressing this unmet need.

The details

MEDIPOST's investigational therapy is an umbilical cord blood-derived allogeneic mesenchymal stem cell therapy designed to treat symptomatic cartilage defects in patients with knee osteoarthritis. The company is focused on generating rigorous clinical evidence that could support a new treatment approach for people living with this condition.

  • MEDIPOST filed the IND amendment on February 13, 2026.
  • Patient enrollment for the Phase III trial is expected to begin in the first half of 2026.

The players

MEDIPOST Inc.

A biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven and degenerative diseases.

Edward Ahn, PhD

Chief Executive Officer of MEDIPOST Inc.

U.S. Food and Drug Administration (FDA)

The federal agency responsible for regulating and supervising the safety of food, drugs, and medical devices in the United States.

Got photos? Submit your photos here. ›

What they’re saying

“Submitting this IND amendment marks an important step toward advancing our U.S. clinical program. Knee osteoarthritis continues to place a significant burden on patients, with limited treatment options that address the underlying disease. Through this study, our focus is on generating rigorous clinical evidence that could support a new treatment approach for people living with this condition.”

— Edward Ahn, PhD, Chief Executive Officer (MEDIPOST Inc.)

“Filing an IND amendment reflects our long-term commitment to advancing science that has the potential to make a meaningful difference for patients.”

— Edward Ahn, PhD, Chief Executive Officer (MEDIPOST Inc.)

What’s next

Patient enrollment for the Phase III trial is expected to begin in the first half of 2026.

The takeaway

MEDIPOST's planned Phase III study aims to further evaluate the potential of its regenerative cell therapy to address the significant unmet need for new treatment options that go beyond symptom management for patients living with knee osteoarthritis.